Synapse - Genitourinary Oncology Service

Results (107)

Validation of a kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa (IFN-alpha): Analysis of the pivotal randomized trial

Meeting Abstract

Wilkerson, J.; Stein, W. D.; Kim, S. T.; Huang, X.; Motzer, R. J.; Fojo, A. T.; Bates, S. E.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Total androgen-receptor gene expression inhibitor therapy (TARGET): A phase II trial of neoadjuvant SAHA (S) followed prostatectomy for patients (pts) with high-risk prostate cancer (pc)

Meeting Abstract

Slovin, S. F.; Fine, S.; Nelson, P.; Steinbrecher, J.; Eastham, J.; Coleman, J.; Touijer, K. A.; Carver, B. S.; Laudone, V.; Scher, H. I.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial

Meeting Abstract

Scher, H. I.; Chi, K. N.; De Wit, R.; Berry, W. R.; Albers, P.; Henick, B.; Venner, P.; Heidenreich, A.; Chu, L.; Heller, G.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer (CRPC)

Meeting Abstract

Rathkopf, D. E.; Danila, D. C.; Chudow, J. J.; Morris, M. J.; Slovin, S. F.; Fine, S.; Fox, J. J.; Larson, S. M.; Rosen, N.; Scher, H. I.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Osanto, S.; Hutson, T. E.; Calvo, E.; Escudier, B. J.; Oudard, S.; Porta, C.; Bracarda, S.; Grunwald, V.; Ravaud, A.; Motzer, R. J.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-alpha)

Meeting Abstract

Patil, S.; Figlin, R. A.; Hutson, T. E.; Michaelson, D.; Negrier, S.; Kim, S. T.; Huang, X.; Motzer, R. J.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial

Meeting Abstract

Montgomery, R. B.; Morris, M. J.; Ryan, C. J.; Stickney, D. R.; Frincke, J. M.; Reading, C. L.; Sarantopoulos, J.; Scher, H. I.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Fluorodeoxyglycose (FDG) PET as an outcome measure for metastatic prostate cancer

Meeting Abstract

Morris, M. J.; Fox, J. J.; Dennis, E. R.; Tse, K.; Flatts, E.; Heller, G.; Jia, X.; Schoder, H.; Larson, S. M.; Scher, H. I.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Long-term responders to sunitinib therapy for metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Molina, A. M.; Jia, X.; Ginsberg, M. S.; Velasco, S.; Feldman, D. R.; Patil, S.; Motzer, R. J.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium

Meeting Abstract

Milowsky, M. I.; Trout, A.; Regazzi, A. M.; Garcia-Grossman, I.; Flaherty, A.; Tickoo, S.; Al-Ahmadie, H.; Bajorin, D. F.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save